Stifel analyst Benjamin Burnett initiated coverage of Crispr Therapeutics with a Hold rating and $52 price target. While CRISPR/Cas9 technology has a path to form the basis of a multi-product platform, it's unclear how investor sentiment regarding this will evolve as other companies are also leveraging a version of CRISPR/Cas9 or other distinct non-CRISPR gene editing technologies, Burnett tells investors in a research note. Further, the analyst believes Crispr shares reflect much of the optimism around the "exceptional" sickle cell disease data in connection with CTX001.